As a different approach, we pretreated platelets with ticagrelor (TCG), a commercial drug that blocks P2Y12R. Strikingly, platelets treated with ticagrelor were insensitive to COVID-19 plasma (Figure 4E). The gene discussed is P2RY12; the disease is COVID-19.